-
Previous
Scrambled shRNA Control Lentivirus
$395.00 – $595.00
-
Next
Human IDO1 shRNA Lentivirus
$595.00 – $1,195.00
Human BIK shRNA Lentivirus
$595.00
Validated human BIK shRNA Lentivirus: High-titer shRNA lentiviral particles specific for human BCL2 interacting killer (BIK). The shRNA has been validated to meet or exceed 70% BIK knockdown efficiency using a specific fluorescence-based method that is more rapid and reliable than qPCR. The shRNA lentivirus is ultra-purified and concentrated to high-titer by PEG precipitation and sucrose gradient centrifugation, and ideal for transducing difficult-to-transfect cells including thawed and/or primary cells.
Available Options:
Specifications
Key Advantages:
- Same Cost For Custom Lentivirus – You can receive any combination of reporter (GFP/RFP/Luc/None) and selection marker (puromycin/blasticidin) for this product, without additional cost, by contacting us. To view our complete list of shRNA vectors, click here.
- Superior knockdown – LipExoGen Validated shRNA Lentiviruses are produced using the third generation system and feature novel, optimized shRNA vectors which express a 19-20 bp shRNA, fluorescent (GFP or RFP) or luminescent (luciferase) reporter, and drug-selection marker (puromycin or blasticidin). Taking advantage of a proprietary prediction algorithm developed in-house, validated shRNA constructs are capable of delivering 70% or more knockdown efficiency with less off-target effects compared to longer or mixed-sequence shRNA/siRNAs.
- Superior validation – All of our pre-made shRNA constructs are validated in-house using a specific fluorescence-based method that is more reliable than traditional qPCR. The validation process leverages bicistronic expression of the target mRNA and fluorescent reporter to confirm the efficacy of the shRNA. As knockdown validation can be readout using basic fluorescence microscopy, this low-cost, streamlined approach allows us to provide a superior-quality product at a price comparable or less than the average competitor.
- Superior accuracy – Polyclonal shRNA-transduced stable cells can be established within 10 days and used for downstream applications while preserving more properties of the parental cells. In this way, high-efficiency knockdown from our validated shRNA lentiviral particles can be advantageous over sgRNA CRISPR-Cas9 systems which select for single cell clones.
- Easily identify transduced cells – Validated shRNA constructs contain both fluorescent reporter and drug selection marker, allowing the flexibility to select transduced cells by puromycin/blasticidin or FACS sorting of GFP/RFP. Luciferase reporters are also available for detecting transduced cells in vitro or in vivo using luminescence-based techniques.
Product Data
Figure 1. Knockdown validation for hBIK-sh2-GFP-Puro. HEK293FT cells were co-transfected with human BIK-RFP bicistronic expression plasmid (red) and plasmids for the indicated shRNAs (GFP, green). After 24-36 hours, fluorescent images of the living cells were acquired by fluorescence microscopy. GFP represents transfection of the shRNA construct, whereas RFP indicates translation of the target mRNA. Higher knockdown efficiencies may be possible in stably-transfected cells. Sr-sh, scrambled shRNA.
Details
LSV-0025 | |
BIK | |
BCL2 interacting killer | |
NM_001197.5 | |
Human |
Recommended Control
Scrambled shRNA Control Lentivirus (mixture of two independent shRNAs), LSV-0024
Custom Orders
If you require a modification to one of our products (for example, change in reporter or other vector component), please request a custom order. We provide a variety of fast and efficient services for the production of high-quality, custom lentiviral particles on demand, usually for the same or comparable price as the listed item.
Or, send us your cells and we will establish a stable shRNA cell line for you using this product. Learn more.
The cDNA lentivirus corresponding to this product is also available upon request, comparable price.
I want to:
Additional Information
Additional Information
BIK | |
BCL2 interacting killer | |
n | NM_001197.5 |
Homo sapiens | |
Alias | BP4; NBK; BIP1 |
Annotation Page | https://www.ncbi.nlm.nih.gov/gene/638 |
Gene IDs | HGNC:HGNC:1051 Ensembl:ENSG00000100290 MIM:603392 |
Entrez Gene Summary | “The protein encoded by this gene shares a critical BH3 domain with other death-promoting proteins, such as BID, BAK, BAD and BAX, that is required for its pro-apoptotic activity, and for interaction with anti-apoptotic members of the BCL2 family, and viral survival-promoting proteins. Since the activity of this protein is suppressed in the presence of survival-promoting proteins, it is suggested as a likely target for anti-apoptotic proteins. [provided by RefSeq, Sep 2011]” |